Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Genentech Inc.

Barbara Hoffman of Piper Jaffray said she wasn't impressed with results of Genentech Inc.'s Phase II trial of the anti-Her2 antibody

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE